Inhalation contract development and manufacturing organisation (CDMO) Bespak has released its first ever Environmental, Social and Governance (ESG) update.
This update provides an overview of Bespak’s actions and progress in key material topics across its value chain.
It also lays out the company's planned future steps relating to improving its sustainability credentials.
Evolving sustainability regulation, as well as individual company ESG commitments, mean the pharmaceutical industry must decrease its carbon footprint.
According to Bespak, CDMOs have a responsibility to help drive this change.
Bringing together the three facets of ESG allows a business to understand its impacts in all aspects including direct and indirect impacts on the planet, people and natural ecosystems.
Bespak will centrally focus on enabling the transition to low carbon pressurised Metered Dose Inhalers (pMDIs), though it will also:
- Develop a flagship ESG strategy
- Complete its first double-materiality assessment
- Map key stakeholders and value chain components
- Verify its baseline scope 1–2 greenhouse gas emissions data
- Establish an ESG & Enterprise Risk Governance Framework
"This ESG update marks an important early chapter for the new Bespak. It reflects the work we’ve done to begin embedding sustainability across the business, from product design and operations to the way we partner with customers and suppliers while planning for the future," noted Bespak's CEO, Chris Hirst.
"It’s taken real commitment from our skilled and dedicated teams to get us here. As we look to the rest of 2025 and beyond, I’m confident we’re building on strong foundations.”
“Our vision is to integrate sustainability across the inhalation supply chain," added Benedicta Bakpa, Head of ESG at Bespak.
"This update outlines the practical steps we’re taking and the groundwork we’ve laid to turn that ambition into action. We’re building the capacity to not only to meet our sustainability commitments, but to exceed them.’’